Mylan NV CEO Heather Bresch, who became a central figure in the public drama that played out earlier this year over the EpiPen (epinephrine) drug pricing scandal, continues to defend the company’s decision to substantially raise the price of the life-saving allergy medicine and put some of the responsibility at other players in the distribution chain.
“We got a lot of things right [with EpiPen], but we got some things wrong,” Bresch acknowledged to a room...





